Vertex Pharmaceuticals Incorporated VRTX Casgevy Commercial Momentum and Pipeline Catalysts Signal Upside Ahead of Partner CRISPR Therapeutics Q1 2026 Earnings OSBC Old Second stock rises 19 percent following Q1 2026 results even as it misses analyst consensus EPS estimates Is Dare Bio DARE stock gaining momentum Q4 2025 EPS Beats Forecasts